which we contrasted binding of the antibiotic trimethoprim (TMP) to chicken dihydrofolate reductase on the one hand with its binding to Escherichia coli dihydrofolate reductase on the other, permit identification of differences that are important in accounting for TMP's selectivity. The crystallographic evidence strongly suggests that loss of a potential hydrogen bond between the 4-amino group of TMP and the backbone carbonyl of Val-11 5 when TMP binds to chicken dihydrofolate reductase but not when it binds to the E. coli reductase is the major factor responsible for this drug's more potent inhibition of bacterial dihydrofolate reductase. A key finding of the current study which is important in understanding why TMP binds differently to chicken and E. coli dihydrofolate reductases is that residues on opposite sides of the active-site cleft in chicken dihydrofolate reductase are about 1.5-2.0 A further apart than are structurally equivalent residues in the E. coli enzyme.
which we contrasted binding of the antibiotic trimethoprim (TMP) to chicken dihydrofolate reductase on the one hand with its binding to Escherichia coli dihydrofolate reductase on the other, permit identification of differences that are important in accounting for TMP's selectivity. The crystallographic evidence strongly suggests that loss of a potential hydrogen bond between the 4-amino group of TMP and the backbone carbonyl of Val-11 5 when TMP binds to chicken dihydrofolate reductase but not when it binds to the E. coli reductase is the major factor responsible for this drug's more potent inhibition of bacterial dihydrofolate reductase. A key finding of the current study which is important in understanding why TMP binds differently to chicken and E. coli dihydrofolate reductases is that residues on opposite sides of the active-site cleft in chicken dihydrofolate reductase are about 1.5-2.0 A further apart than are structurally equivalent residues in the E. coli enzyme.
X-ray structural studies reported in our previous paper (Matthews et al., 1985) showed that the antibiotic TMP' binds differently at the active sites of chicken and Escherichia coli dihydrofolate reductases. Qualitative structural comparison of these two enzyme:inhibitor complexes enabled us to give a detailed description of the differences in TMP-binding geometry. However, on the basis of these data alone, no conclusions could be reached concerning which of the observed stereochemical differences might be important in accounting for TMP's much weaker binding to the chicken enzyme. In the present paper, we further report on the use of x-raydiffraction methods to investigate inhibition of chicken di-* This research was supported by Research Grants CA 17374 and RR 00757 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The abbreviations used are: TMP, trimethoprim; DAMP, 2,4-diamino-5-(l-adamantyl)-6-rnethylpyrimidine; MTX, methotrexate. hydrofolate reductase by selected pyrimidines and triazines, some of which, in contrast to TMP, are potent inhibitors of this enzyme. These results serve to identify favorable enzyme ligand interactions common to tight-binding chicken dihydrofolate reductase inhibitors, and in conjunction with our earlier structures for TMP bound to the chicken and E. coli enzymes, provide insight as to why TMP binds strongly to the E. coli enzyme but poorly to the vertebrate enzyme. Our objective is to understand which of the various stereochemical factors are important in accounting for this selectivity.
In addition, we address here the related question of why TMP binds to chicken dihydrofolate reductase and E. coli dihydrofolate reductase with different geometries. A key finding which suggests a possible explanation is that the binding cleft of chicken dihydrofolate reductase is, in simplified terms, approximately 2 A wider than in the E. coli enzyme.
GEOMETRY OF INHIBITOR BINDING TO CHICKEN DIHYDROFOLATE REDUCTASE
Crystals, Data Collection, and Difference Maps-For each inhibitor listed in Table I , a ternary complex was prepared by soaking selected crystals of the holoenzyme for 1 week at 4 "C in artificial mother liquor solutions containing 0.05 M sodium cacodylate, 0.005 M calcium acetate, 0.001 M NADPH, 40% ethanol, and a saturating concentration of the inhibitor at pH 6.8. In each case, one crystal was used to collect x-ray diffraction data to a resolution of 2.9 A, except for the chicken enzyme complexes with TMP and with its triethyl isostere, which were analyzed at 2.2-A resolution and required three and two crystals, respectively. Approximately 20% of the measured x-ray intensities from each crystal were duplicate observations of reflections constituting the unique set or were symmetry related to reflections in that set. Individual data sets had internal R,,,
between 0.022 and 0.34, while merged diffraction data from multiple crystals scaled at 0.033 and 0.028 for TMP and its triethyl isostere, respectively. Data collection procedures were similar to those described in Volz et al. (1982) . Crystal deterioration was monitored by periodic intensity checks of four standard reflections. At the termination of data collection, the average intensity decrease for any given crystal was between 0 and 10%. Cell parameters for all ternary complexes discussed here are the same as those for the holoenzyme (Volz et al., 1982) within 0.5%. Difference electron-density maps were computed using coefficients (Fernery -Fholo)eie, where Fternaw is an observed structure factor amplitude for one of the ternary complexes, Fh& is the corresponding structure factor amplitude for the chicken dihydrofolate reductase holoenzyme, and (Y is its Hansch et al., 1984. ' C. Hansch, private communication.
e Denotes an 160 measurement.
B. Roth, private communication.
e Kompis et al., 1980. f Denotes inhibition of rat liver dihydrofolate reductase. Ho et al., 1972 . Denotes inhibition of mouse S180 dihydrofolate reductase.
phase calculated from our current refined model (Matthews et al., 1985) . An Evans and Sutherland Picture System I1 was used for difference-map display and interpretation. 2,4-Diamirw-5-phenyl-s-triazines-The six triazines studied here as ternary complexes with chicken dihydrofolate reductase are distinguished from one another by a characteristic substituent in the 3' or 4' position of the phenyl ring (Table I) . These substituents range in size and complexity from simple monoatomic and diatomic moieties up to large branching side chains. Comparison of the six structures indicates that, within our ability to distinguish at this resolution (2.9 A), the respective triazine rings and their phenyl side chains all bind identically to chicken dihydrofolate reductase. Thus, at least for these triazines, we can make the generalization that, while the detailed nature of the 3' or 4' substituent is important in determining the relative ordering of K , values, it is the structure of the parent phenyltriazine itself that governs the overall mode of binding at the active site of dihydrofolate reductase. In an earlier paper (Volz et al., 1982) , we analyzed the dihydrofolate reductase. NADPH. methoxyphenyltriazine ternary complex by difference Fourier methods, but using an unrefined model for the holoenzyme and the original multiple isomorphous replacement phases. The major conclusions from this earlier description remain unchanged following high-resolution refinement of the holoenzyme, and we present here only a brief summary of phenyltriazine binding followed by an accounting of how the longer 3' substituents for two of the inhibitors are accommodated near the enzyme's surface. 11 when bound to dihydrofolate reductase (Baker and Jordaan, 1965) , interacts with the side chain of Glu-30 by way of charge-mediated hydrogen bonds at N1 and the 2-amino group. In addition, the 2-amino group donates a second hydrogen bond to a highly ordered and structurally invariant bound water molecule (Bolin et al., 1982) . Additional hydrogen bonds occur between the inhibitor's 4-amino group and the carbonyl oxygens of . This arrangement of hydrogen bonds around the pyrimidine ring is exactly analogous to that seen at the pteridine ring of MTX when bound to both E. coli and Lactobacillus casei dihydrofolate reductases, and will be the subject of additional discussion in the following section.
In addition to the several polar interactions between phenyltriazine and dihydrofolate reductase, numerous van der Waals contacts occur as well. The triazine-binding pocket comprises portions of , and the carboxamide group of NADPH. For each of the six triazines studied here, the N5 phenyl substituent is located at the left of the binding cleft as viewed in Fig. 1 . Its exact positioning is apparently influenced by three residues in helix aC, namely Thr-56, Ser-59, and Ile-60. In addition, the pyridine ring of NADPH and the side chain of Leu-22 are positioned adjacent to the lower edge of the inhibitor's phenyl group. A principal torsion angle common to all the phenyltriazines involves rotation about the N5-C single bond, and, in each case studied here, that angle is about 70" (where the perpendicular conformation would have a torsion angle of 90").
In two instances, we have examined phenyltriazine inhibitors bearing large substituents at the 3' position of the phenyl ring. Both of these long side chains bind in a narrow channel which leads from the extreme upper portion of the active-site cleft to the protein surface. This groove is bounded primarily by five bulky hydrophobic residues (Tyr-31, Phe-34, Ile-60, Pro-61, and Leu-67) which account for most of the direct protein-ligand interactions with these longer 3' substituents.
The acetamide group of one of the inhibitors (X = CH20CsH4-3'-NHCOCH3, indicated in Fig. 1 ) binds near the side chains of Gln-35 and Asn-64, which form exterior surfaces of the side channel. Difference density for the acetamide group is diffuse and ill defined, suggesting that several conformations are present, one or more of which may involve hydrogen bonding to the side chain carboxamide of residue 35 or 64. For the still longer alkoxy analog (X = O(CH2)&H3, difference density at the 3' substituent is strong (250) for the oxygen and the first two attached methylene groups, but much weaker (~2 . 5 0 ) for the following two methylenes, at which point the side chain reaches the protein surface and the remaining hydrocarbon tail becomes totally disordered. These observations are consistent with kinetic studies of 3'-O(CH2)-CH3 phenyltriazine inhibitor binding to chicken dihydrofolate reductase where it has been shown that K; decreases systematically as n increases from 0 to 4 but for n ? 5 no additional inhibition is observed (Hansch et al., 1984) .
Upon binding to chicken dihydrofolate reductase, each of the six triazine inhibitors causes small adjustments in protein conformation along heli? aB. The side chains of Glu-30 and Tyr-31 move about 0.8 A, while much smaller repositionings of perhaps 0.1-0.2 A occur at backbone atoms of residues 31-32, 35, 37, and 39.
2,4-Diamino-5-(1 -adamantyl)-6-methylpyrimidine-DAMP binds to chicken dihydrofolate reductase in a manner very similar to that observed for the phenyltriazines. All five hydrogen bonds between the protein and the pyrimidine ring are analogous to those described above for the phenyltriazines. There is, however, as much as a 20-25" variation in the tilt of the respective heterocyclic rings which probably results from DAMP'S slightly different requirements for optimizing hydrogen bonding. This effect is due to the pyrimidine and its substituents' distortion from coplanarity caused by steric interference of the six methyl hydrogens with the adamantyl ring. (Cody and Zakrzewski, 1982) . As can be seen in Fig. 2 , the adamantyl side chain is positioned in the same pocket occupied by the phenyl portion of phenyltriazine inhibitors. However, because of its greater bulk, the adamantyl group makes more extensive van der Waals contact with the surrounding protein side chains. The difference map indicates that small movements occur at the side chains of Glu-30 and Tyr-31, as well as in the backbone of aB. These perturbations are analogous to those described above in the case of phenyltriazine binding. The current resolution (2.9 A ) is insufficient to define exactly how the adamantyl side chain is oriented with respect to rotation about the bond connecting it to the pyrimidine ring.
The Triethyl Isostere of Trimethoprim-It is apparent from the difference maps that this close structural analog of TMP binds to chicken dihydrofolate reductase in a manner similar to that for TMP. As was seen for TMP itself (Matthews et al., 1985) , a potential hydrogen bond between the inhibitor's 4-amino group and the backbone carbonyl of Val-115 is absent, owing to a 1-A displacement of the pyrimidine ring toward helix aB as compared to the pyrimidine's position in, for example, the adamantyl analog. The side chain of Tyr-31 undergoes a conformational change accompanying formation of the ternary complex analogous to that described in the previous paper (Matthews et al., 1985) for TMP binding to chicken dihydrofolate reductase. However, the crystallographic evidence demonstrates that there are slight geometrical differences in how the respective benzyl side chains of TMP and its triethyl isostere are oriented in the binding cleft. The benzene rings themselves are tilted somewhat differently, resulting in positional differences of approximately 1 A for corresponding atoms at the edge of the rings. In addition, torsion angles for corresponding substituents in the benzene rings are not identical. In particular, the meta-ethyl group positioned at the back of the binding cavity appears to be in a different conformation than that for the corresponding methoxy group of TMP.
4'-Isopropenyl Analog of Trimethoprim-The major difference in binding to chicken dihydrofolate reductase between TMP and its 4'-isopropenyl analog is that the latter compound, unlike TMP itself, does not cause repositioning of the Tyr-31 side chain. This observation will play a key role in our analysis in the following section of structural factors important for inhibitor selectivity. In both molecules the respective pyrimidines bind identically, although rotational differences of 20-30" occur for each of the torsion angles about the benzyl carbon-carbon bonds. The net effect of these differences is that the benzene group in the 4'-isopropenyl analog is rotated slightly back (8,) and down (8,) compared to its position in TMP and, in this way, avoids unacceptably close steric contact with the side chain of Tyr-31. Additionally, several small adjustments in protein structure accompany binding of the 4'-isopropenyl analog. These repositionings are the same as those noted previously for TMP (Matthews et al., 1985) .
STEREOCHEMICAL BASIS FOR INHIBITOR SELECTIVITY
In this section we address the question of how stereochemical differences between TMP binding to chicken and E. coli dihydrofolate reductases might translate into differences in binding energy and thereby rationalize TMP selectivity. Of course, K, differences for TMP bound to these two enzymes really reflect differences in free energy of binding. However, since a static, structure-based approach cannot easily make even qualitative predictions concerning entropy effects, we must limit our discussion to enthalpy considerations. But, in this regard, it is worth pointing out that both MTX and folate binding to chicken dihydrofolate reductase have been shown to be primarily enthalpy-driven processes (Subramanigan and Kaufman, 1978) .
In the previous paper (Matthews et al., 1985) , we identified four stereochemical factors that distinguish T M P binding to E. coli dihydrofolate reductase from that found for T M P binding to the chicken enzyme. These are 1) differences in exact positioning of the 2,4-diaminopyrimidine ring, 2) differences in the benzyl group-binding sites, 3) torsional differences about both benzyl carbon-carbon bonds, and 4) a large change in conformation for the side chain of Tyr-31 when T M P binds to chicken dihydrofolate reductase. Each of these factors will now be considered in an effort to judge its probable importance for T M P selectivity.
2,4-Diamino Heterocycle Binding-All of the tightly binding inhibitors of chicken dihydrofolate reductase studied here have their respective 2,4-diamino heterocyclic rings similarly positioned at the active site of the chicken enzyme. The side chain of Glu-30 closely approaches the protonated N1 and the %amino group in a geometry consistent with the existence of two hydrogen bonds and a charge-charge interaction. In addition, the 4-amino group donates a pair of hydrogen bonds to the backbone carbonyl oxygens of Ile-7 and Val-115. Exactly analogous interactions exist for T M P bound to E. coli dihydrofolate reductase and also for methotrexate in complexes with dihydrofolate reductase from both E. coli and L. casei. Only for inhibitors that are weakly bound to chicken dihydrofolate reductase (i.e. TMP, its triethyl isostere, and its 4'-isopropenyl analog) do we observe an altered binding geometry wherein the 2,4-diamino heterocycle occupies a position approximately l A closer to NB where it can no longer hydrogen bond to the carbonyl oxygen of Val-115. Thus, the crystallographic evidence strongly suggests that loss of this hydrogen bond is a significant factor in TMP's low affinity for chicken dihydrofolate reductase and, therefore, must be an important determinant of the drug's selectivity. We will have more to say shortly concerning why TMP's heterocyclic ring binds to chicken dihydrofolate reductase in this unusual mode.
Benzyl Side Chain Binding-It was shown in the previous paper (Matthews et al., 1985) that, for T M P bound to E. coli dihydrofolate reductase, the inhibitor's benzyl side chain is positioned low in the active-site pocket, pointing down toward the nicotinamide-binding site (the "down" conformation which positions the inhibitor side chain in the "lower" cleft), whereas in chicken dihydrofolate reductase the benzyl group is accommodated in a side channel running upward and away from the cofactor (the "up" conformation which positions the inhibitor side chain in the "upper" cleft). Clearly, interactions between the benzyl group and the enzyme are different in these two cases, and difficult to quantify. To what extent is T M P selectivity due to this dramatic difference in binding interactions? Fig. 2 If this were not the case and the upper binding cleft for chicken dihydrofolate reductase were an inherently inferior hydrophobic binding site, then it would follow that all 2,4-diamino heterocycles with side chains bound here should be weak inhibitors of chicken dihydrofolate reductase, which clearly is not the case.
Analysis of NMR data for T M P bound to E. coli, L. casei, and mouse L1210 dihydrofolate reductase also demonstrates that the benzyl side chain is oriented differently in bacterial and vertebrate dihydrofolate reductase. T M P complexes (Birdsall et al., 1983) although the methodology used to derive the predicted conformation for T M P bound to the mouse enzyme is open to criticism (Matthews et al., 1985) . Birdsall et al. (1983) attributed selectivity primarily to the fact that "the trimethoxybenzyl ring must occupy a significantly different part of the binding site in the two different enzymes," discounting any role for differences in pyrimidine binding because ". . . the binding energies of 2,4-diaminopyrimidine to the L1210 enzyme and to the L. casei enzyme are very similar." We have reached the opposite conclusion based on the discussion in the preceding paragraph and on our direct observation of structural differences in the location of TMP's pyrimidine ring when bound to E. coli and chicken dihydrofolate reductase. The similarity in binding energy for 2,4-diaminopyrimidine in complexes with L. casei and L1210 dihydrofolate reductases is irrelevant for discussion of TMP selectivity since, as we have seen, only when the diaminopyrimidine also has an attached trisubstituted benzyl side chain does its relative position in chicken dihydrofolate reductase differ from that in the corresponding complex with the E. coli reductase. It is this binding difference which for chicken dihydrofolate reductase results in the loss of a hydrogen bond between TMP's 4-amino group and the carbonyl of Val-115 that must play a crucial role in accounting for TMP's enhanced affinity for bacterial dihydrofolate reductase.
Conformational Change at Tyr-31 "Results presented above support the view that the change in side chain conformation of Tyr-31,c12 upon binding TMP requires very little energy and thus makes a negligible contribution to lowering the affinity of chicken dihydrofolate reductase for TMP. We showed in the previous paper (Matthews et al., 1985) that, when TMP binds to the chicken holoenzyme, the Tyr-31 side chain is rotated down into a new position (average movement is 5.4 A for all atoms beyond Cp), where it can hydrogen bond via an intervening water molecule to the backbone carbonyl oxygen of Trp-24. In a foregoing paragraph, we discussed binding of the 4'-isopropenyl analog of TMP to chicken dihydrofolate reductase and noted that this inhibitor's stereochemical interactions with the enzyme are very similar to those observed for TMP except for the absence of the induced conformational change involving Tyr-31. Kompis et al., (1980) have reported that the 4'-isopropenyl derivative binds to rat liver dihydrofolate reductase only one-third as well as TMP and, although corresponding inhibitory activities against the chicken enzyme are unavailable, they undoubtedly are similar. If the movement of Tyr-31 were energetically costly, one would expect TMP to bind significantly less well to chicken dihydrofolate reductase than does its 4'-isopropenyl analog, the opposite of what is actually observed. Conformation of Bound TMP-As noted above and discussed at length in the previous paper (Matthews et al., 1985) , when TMP binds to chicken dihydrofolate reductase, the trimethoxybenzyl group occupies a portion of the active site quite distinct from its binding site in the E. coli dihydrofolate reductase complex, whereas the 2,4-diaminopyrimidine moieties are oriented similarly in the two cases (but not identically; see above). It is apparent, then, that the torsion angles O1 and 02, which define rotation of the TMP side chain with respect to the pyrimidine ring, must also differ in these two complexes. As reported in the previous paper, these values are (-85", 102") and (177", 76") for TMP bound to chicken and E. coli dihydrofolate reductases, respectively. It is therefore of interest to inquire about the relative stabilities of these two conformations in the isolated TMP molecule, since any internal energy difference between these two conformers will appear in the respective enzyme. TMP complexes as a difference in Ki.
One approach would be to examine small molecule crystal structures of TMP and other closely related benzylpyrimidines in order to ascertain whether or not certain side-chain conformations are favored. Side-chain torsion angles (01, 0,) derived from seven such crystal structure analyses are given in Table 11 . The conformations tabulated there fall neatly into two groups. Each of the first four molecules has a value for O1 between -65" and -90" and, in every case, the corresponding value of O2 is close to 150". The second group, The symbols ec and cl are appended to residue numbers to indicate the E. coli and chicken liver enzymes, respectively. consisting of the hydrobromide salt of TMP, the 4'-isopropenyl analog of TMP, and a molecular complex between TMP and sulfamethoxazole, has an average O1 of 185" and 0, around 95".
It is notable that the bound conformation for TMP in its binary complex with E. coli dihydrofolate reductase differs by less than 20" in both O1 and O2 from the average conformation observed for TMP-like molecules of group 11. Therefore, these experimental results at least suggest the possibility that, in the E. coli dihydrofolate reductase binary complex, TMP exists in a low-energy conformation.
Further evidence supporting this hypothesis comes from molecular mechanics calculations of the conformational potential energy for free TMP as a function of O1 and 02. According to these computations (Koetzle and Williams, 1976) , the region of conformational space sampled by molecules in group I1 and by TMP bound to E. coli dihydrofolate reductase exists as a broad depression in the potential-energy surface differing by only about 1 kcal/mol from the global minimum.
Turning now to a consideration of TMP's conformation when bound to chicken dihydrofolate reductase, we note that the conformation of TMP in the chicken dihydrofolate reductase ternary complex differs somewhat from that observed for any of the benzylpyrimidine crystal structures listed in Table   11 . The value of -85" for O1 falls within the range observed for this torsion angle in the free TMP-like molecules of group I. However, O2 differs by 50" from the group I consensus value of 153". Therefore, on the basis of these data alone, we cannot yet dismiss the possibility that TMP binds to the chicken enzyme with an elevated conformational potential energy which would in turn reduce the drug's affinity for chicken dihydrofolate reductase. However, the calculations of Koetzle and Williams (1976) appear to rule out such a possibility. Their results show that, for O1 values near -go", the conformational potential energy of TMP has almost no functional dependence on 02, and, of equal importance, the computed energy throughout this region of the potential energy surface differs from that for TMP bound to E. coli dihydrofolate reductase by less than 1 kcal/mol. In summary, then, the combined evidence from smallmolecule crystallography and theoretical computations supports the notion that the stereochemically dissimilar conformations of TMP, when bound to chicken and E. coli dihydrofolate reductases, have similar energies and it seems unlikely, therefore, that conformational differences about the benzyl carbon play a major role in TMP selectivity.
Effects of Substituents in the Benzyl
Ring-Up to this point, our analysis of the structural basis for TMP selectivity could apply equally well to any of a number of 2,4-diamino-5-(trisubstituted)benzylpyrimidines because as a class these inhibitors are markedly more effective against bacterial dihydrofolate reductases than aginst vertebrate dihydrofolate reductases (Roth, 1983; and references therein) . But in the particular case of TMP, selectivity seems to have been "fine tuned" by the presence of three methoxyl groups in the benzyl side chain. (Baccanari et al., 1983; Hyde and Roth, 1982) . For example, although TMP and its triethyl isostere bind equally well to E. coli dihydrofolate reductase, TMP itself binds less tightly to the vertebrate dihydrofolate reductase by a factor of 10 as compared with the triethyl isostere. Thus, for reasons that are as yet obscure, some effect due to the presence of three methoxyl substituents on the benzyl side chain destabilizes binding to vertebrate dihydrofolate reductases and this effect accounts for at least a factor of 10 in overall selectivity. (1976) .
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WHY DOES TRIMETHOPRIM BIND DIFFERENTLY TO E. COLI AND CHICKEN DIHYDROFOLATE REDUCTASE?
The previous paper (Matthews et al., 1985) described geometrical differences in how T M P binds to chicken and E. coli dihydrofolate reductases. In this paper, we have so far been concerned with explaining how these stereochemical differences contribute to overall T M P selectivity. In what follows, we go on to explore the structural basis for why it is that T M P binds in a different way to two highly homologous enzymes from different species.
In our original report on the structure of chicken dihydrofolate reductase we noted that, despite the high degree of overall structural homology between the chicken and E. coli enzymes, there were differences of 1-3 A in the relative placement of corresponding elements of secondary structure (Volz et al., 1982) . Now that the structures have been refined with high-resolution diffraction data, these differences can be characterized more quantitatively. To anticipate the discussion below, we find that residues on opposite sides of the active site cleft in chicken dihydrofolate reductase are about 1.5-2.0 A further apart than are structurally equivalent residues in the E. coli enzyme. An important consequence is that, if the benzyl side chain of T M P were constrained to occupy the lower part of the active-site cleft in the chicken enzyme, an energetically unfavorable gap would occur between the benzyl group and nearby protein side chains.
The most frequently used procedure for comparing two closely related structures is the method of molecular superposition, where one attempts to rotate and translate one structure relative to the other until a "best fit" is obtained according to some statistical criterion. This method usually results in a superposition in which differences are distributed over the entire set of atomic positions being compared. An undesirable consequence is that the relative importance of certain differences may be lost or obscured. A more informative method is as follows: for each of the two molecules being Table 111 presents all unique A,, values for two pyrimidine nitrogen atoms of TMP and for eight a-carbon atoms of residues known to interact with T M P in either the vertebrate or bacterial enzyme complexes.
It is apparent from Table I11 that there is a significant quantitative difference between binding-site geometries in chicken and in E. coli dihydrofolate reductase. This difference cannot be attributed to the presence of NADPH in the chicken dihydrofolate reductase ternary complex, since the same difference-distance comparison between the chicken apo-and holoenzyme structures3 show that cofactor binding does not alter these a-carbon coordinates.
Inspection of Table 111 shows that the pyrimidine N1 nitrogen of T M P is positioned approximately 1 A farther from ec) on the left side of the cleft, and 0.75 A closer to ec) on the right side of the cleft (see Fig.  2 ) in the chicken enzyme than is the corresponding atom of T M P bound to E. coli dihydrofolate reductase. This observation quantifies our earlier conclusion that the inhibitor is inserted more deeper into the active site of the chicken enzyme (Matthews et al., 1985) .
Particularly noteworthy are the large matrix elements connecting ec) and all other a-carbons in Table  111 . ec ) is located at the end of aC on the left side of the binding site as seen in Fig. 2 , and is the residue providing most of the van der Waals contacts on this side with the benzyl group of T M P in the lower binding cleft. conclusively demonstrate that the TMP side chain cannot be favorably accommodated in the lower cavity of vertebrate dihydrofolate reductase. Specifically, if hydrophobic interactions on the left side of the cleft of chicken dihydrofolate reductase between the side chain of Ile-60 and a hypothetical trimethoxybenzyl group of TMP in the down conformation are required to be similar to the corresponding interactions found for the E. coli dihydrofolate reductase .TMP binary complex, then it is not possible to position the side chain of Tyr-31,cl (or the corresponding Phe side chain of other vertebrate dihydrofolate reductases) to provide favorable hydrophobic contacts on the right side of the cleft analogous to those provided by Leu-28 in the E. coli enzyme. In other words, a gap would be left between the benzyl group and the enzyme. The conclusion is the same regardless of whether one assumes the side chain conformation for Tyr-31 observed in the holoenzyme, or alternatively uses the apparently equal energy conformation having the phenol group down near Trp-24. In the latter case, the side chain of residue 31 cannot approach closer than 6 A to TMP.
We believe that the added width of the active-site cleft in chicken dihydrofolate reductase compared to the corresponding cleft in the E. coli reductase is probably a direct result of a three-amino acid insertion which occurs in all vertebrate dihydrofolate reductases immediately following the termination of helix LYC. As a result, the 6 residues in chicken dihydrofolate reductase directly following this insertion are displaced slightly further away from helix a B on the opposite side of the cleft compared to the analogous geometrical arrangement in the E. coli reductase.
These geometrical considerations also suggest an explanation for the curious observation that all five vertebrate dihydrofolate reductases of known sequence, including the human enzyme, have glutamate at position 30 whereas primary sequence determinations for four bacterial reductases reveal the presence of aspartate at the structurally corresponding location. Examination of Table I11 shows that the largest average difference distances occur when one of the atoms is either Ca-30,cl or Ca-60,cl. This observation implies that the relative positioning of these atoms is different in chicken and E. coli dihydrofolate reductase. In fact, the distance between them is some 2 A greater in the chicken than in the E. coli enzyme. We know that 2,4-diaminopteridines such as MTX bind in close proximity to both residues 30,cl and 60,cl in E. coli and L. casei dihydrofolate reductases and our model predicts that, in the case of substrates as well, the ligand is in contact with both these residues (Bolin et al., 1982) . Therefore, in order that the geometrical relationship betwen the carboxylate group and the left side of the active site cleft be preserved in the more spacious active site of the chicken enzyme, the invariant asparate in bacterial dihydrofolate reductases has been replaced in vertebrate dihydrofolate reductases by an amino acid having a lengthtened but functionally equivalent side chain, i.e. glutamate.
SUMMARY AND CONCLUSIONS
On the basis of the preceding analysis, we offer the following generalizations. 1) For each species of dihydrofolate reductase there are two potential binding sites, the upper and lower clefts, for inhibitor side chains. 2) Both upper and lower clefts are larger in the chicken enzyme. 3) In general, good inhibitors of vertebrate dihydrofolate reductases (e.g. phenyltriazines) derive their enhanced affinity for the vertebrate enzyme from favorable van der Waals interactions in the upper cleft. 4) Inhibitors having opposite specificity (e.g. TMP) make favorable van der Waals interactions with the lower cleft of the bacterial enzyme but can't fit into the potential upper cleft. 5) Inhibitors with strong affinity for both classes of enzymes, such as MTX, partially overlap both sites (Matthews et al., 1977; Bolin et al., 1982) .3 6) It is possible for poor inhibitors of vertebrate dihydrofolate reductase (e.g. certain benzylpyrimidines like TMP) to position their side chains in the upper cleft. What makes them "poor" compared to DAMP or various triazines studied here which also bind to the upper cleft is that the extra bridging methylene group in TMP forces the 2,4-diaminopyrimidine ring closer to aB causing disruption of the 4-amino to Val-115 C=O hydrogen bond. Inhibitors having a phenyl or adamantyl group directly attached to the 5 position of the 2,4-dlaminoheterocycle, on the other hand, appear to be of just the right length to fit into the upper cleft without disrupting hydrogen bonding between the enzyme and the 2,4-diaminoheterocyclic moiety.
The situation is different for the bacterial enzyme. Although an upper cleft also exists in E. coli dihydrofolate reductase (partially filled by an ordered solvent molecule and bounded by side chains in only "loose" van der Waals contact), it is smaller in width by about 1.5-2.0 A. This leads to the prediction that phenyltriazines probably will not bind to bacterial dihydrofolate reductases at the upper cleft in a geometry analogous to that observed for binding to chicken dihydrofolate reductase. One possibility is that a phenyltriazine's phenyl side chain (when bound to E. coli dihydrofolate reductase) could be positioned lower in the active-site pocket where the width of the cleft is somewhat larger. However, unlike a benzylpyrimidine, phenyltriazine has no side chain torsional freedom in relation to the heterocycle except for simple rotation about the single bond connecting the two rings. Thus, for phenyltriazine binding to E.
coli dihydrofolate reductase, a downward displacement of the phenyl side chain compared to its position in the chicken enzyme would require a corresponding repositioning of the triazine ring itself, presumably resulting in decreased binding. An alternate possibility is that the phenyl side chain does occupy the "upper" cleft of the E. coli enzyme but that the 2,4-diaminotriazine ring is inserted further in toward aB, thereby disrupting hydrogen bonding at the 4-amino group, a situation qualitatively analogous to that found for T M P binding to chicken dihydrofolate reductase.
As far as we know, the x-ray studies reported here provide the first detailed account of the structural basis underlying the species selectivity of a drug (TMP in this case). What have we learned that might be generally applicable for understanding protein-ligand interactions?
One lession is that subtle geometrical differences between the binding sites of homologous enzymes can manifest themselves as large differences in the geometry of ligand binding and hence as large differences in ligand affinity. Another lesson to be emphasized is that these geometrical effects can be the result of structural variations that are remote from the binding site, both in sequence and in distance. A corollary of these two observations, given the primitive state of proteinstructure prediction, is that it would have been difficult to understand the enhanced binding of TMP to bacterial as compared with vertebrate dihydrofolate reductase from, for example, model-building experiments utilizing the bacterial structure plus only the vertebrate sequence. In retrospect, painstaking x-ray studies such as these were essential.
On the bright side, however, the success of these x-ray studies in rationalizing T M P selectivity suggests that it will be feasible to design selective inhibitors once the target receptors have been purified and crystallized (probably by cloning, amplifying, and overexpressing the genes). One can readily imagine an iterative experimental approach. Starting with a new synthetic inhibitor molecule, representing an initial approximation, the geometry of its interaction with the target receptor is examined crystallographically and the design of the inhibitor revised to enhance selectivity. A second molecular approximation is then synthesized and similarly examined-and so on. By this means, the long heralded goal of a receptor-based structural approach to the design of drugs may soon be achieved.
